As integrative and emerging therapies grow in popularity, thousands of healthcare providers across Europe and the United States are delivering non-approved treatments for conditions like Parkinson’s Disease, Alzheimer’s, and other neurodegenerative disorders—without the benefit of standardized data systems to track efficacy, safety, or patient outcomes.
Performance Medical Technologies (PMT) is building a secure, AI-driven platform to close this gap—offering clinicians the tools to document, analyze, and elevate care with real-time outcomes tracking, even before therapies receive formal regulatory approval.
Across Italy and the broader EU, clinicians are increasingly turning to various non-traditional interventions to address neurodegenerative conditions. However, without a centralized system for gathering and analyzing treatment data, providers face serious limitations:
Italy—especially regions like Friuli Venezia Giulia (FVG)—offers a unique environment to pioneer this system:
PMT’s platform is being piloted with Italian providers to offer a compliant, secure, and user-friendly system for real-world evidence capture—positioning clinics to participate in future clinical trials, regulatory submissions, and international data collaborations.
By helping providers document safety, effectiveness, and treatment variability, PMT’s system does more than just streamline operations—it generates the real-world data needed to support formal clinical validation in both the U.S. and EU.
Whether you’re a physician in Milan offering a therapy for neuroprotection, or a research site in Virginia preparing for a clinical trial, our system gives you the tools to operate ethically, efficiently, and with an eye toward regulatory readiness.
If you’re a provider using non-approved therapies, it’s time to future-proof your practice. PMT’s AI-powered data system turns every patient interaction into clinical insight—and every clinic into a research ally.
Together, we can advance therapies from anecdote to approval—one data point at a time.
